First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.
According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.
